University Health Network

Abalos Therapeutics Gmbh

Harbins Ruhr Bioscience, Inc.

Merck Patent Gmbh

Universitaet Duisburg-essen

Karl Lang

Tak Wah Mak

Pamela S Ohashi

Michael W Tusche

Philipp Lang

Dirk Brenner

Gloria Lin

Erich Gulbins

Judith Bezgovsek

Halime Kalkavan

Norbert Beier

Rolf Gericke

Thomas Fuchss

Florian Lang

Bernhard Singer

Phillipp Lang

Michael Bergerhausen

Hilal Bhat

Cornelia Hardt

Fan Steven Zhou

Vikas Duhan

Vishal Khairnar

The invention relates to arenaviruses for use in the treatment and/or prevention of tumors and also a method for preparing arenaviruses with (improved) tumor-regressive properties.

Administering a lymphocytic choriomeningtitis virus (LCMV) with improved tumor regression properties

The invention relates to a mutant of an arenavirus having improved antitumoral properties. The invention also relates to a method of generating such an arenavirus mutant, related pharmaceutical compositions, medical uses, methods of treatment, and isolated proteins and nucleic acids.

Method for producing an antitumoral arenavirus as well as arenavirus mutants

Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.

Sphingoid compounds for prophylaxis and/or therapy of a viral infection

Method of enhancing innate immune responses against a tumor comprising administering lymphocytic choriomeningitis virus (LCMV)

The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein.

Methods and compositions for modulating toso activity

An anti-CEACAM1 antibody includes at least one antibody heavy chain (V) domain having antigen binding sites CDR1, CDR2and CDR3, and at least one antibody light chain (V) domain having antigen binding sites CDR1, CDR2and CDR3. The antigen binding site CDR2has a sequence homology of at least 80% to the amino acid sequence WINTYTGEPT (SEQ ID No. 21).

Immunostimulatory anti-CEACAM1 antibody

Methods and compositions for modulating Toso activity

The present invention relates to a compound of formulas I, Ia, Ib and II, wherein R1 to R11 are herein defined.

SGK1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas

Growing community of inventors

Essen, Germany

Karl Lang